Table 2:

Comparison of serum CA125, HE4, and CEA levels among patients with difference biological behaviours of OC (x̄±s)

Group	The number of patients	CA125 (U/mL)	t	P	HE4 (pmol/m)	t	P	CEA (ng/ml)	t	P
Clinical staging
Stage I–II	46	64.58±11.62	2.654	0.038	318.54±55.06	2.936	0.026	21.29±4.63	3.445	0.014
Stage III–IV	76	178.35±41.27c			668.23±105.61c			108.73±24.96c
Differentiation
High and moderate differentiation	48	57.47±9.48	2.895	0.028	276.88±44.29	3.617	0.011	18.19±4.36		0.029
Low differentiation	74	186.23±43.46c			705.31±109.85c			112.34±32.61c
Ascites
No	55	71.57±12.11	2.723	0.034	298.36±41.41	3.641	0.011	34.32±5.69	3.544	0.012
Yes	67	188.96±41.37c			732.25±111.7c			109.37±20.39c
Lymph node metastasis
No	57	73.58±10.30	2.572	0.042	370.17±44.10	2.854	0.029	38.51±6.87	2.953	0.026
Yes	65	190.75±44.31c			682.35±100.11c			108.76±22.78c
Distant metastasis
No	110	110.32±17.31	2.945	0.026	472.32±57.70	3.856	0.008	47.47±7.41	3.989	0.007
Yes	12	372.02±84.01c			1123.27±158.64c			265.09±54.05c
Recurrence
No	93	35.87±4.81	3.127	0.020	145.25±23.59	6.390	0.001	4.63±1.18	5.834	0.001
Yes	29	325.36±92.44c			986.37±129.51c			230.39±38.68c
Treatment
Before treatment	122	135.69±30.12c	3.442	0.014	536.14±74.51c	4.920	0.003	75.29±14.92	5.139	0.002
After treatment	122	38.29±6.67			152.36±23.06			5.01±1.25c

Note:

^cindicates P<0.05 in terms of intro-group comparison